Sensei biotherapeutics announces clinical supply agreement with regeneron for phase 1/2 clinical trial evaluating sns-101, a conditionally active vista-blocking antibody, in combination with libtayo® (cemiplimab) in solid tumors

Boston, jan. 05, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced a clinical supply agreement with regeneron for its anti-pd1 therapy libtayo® (cemiplimab). the supply agreement supports the evaluation of sns-101, a conditionally active vista-blocking antibody, in combination with libtayo® in a phase 1/2 trial in solid tumors. sensei is on track to submit an investigational new drug application for sns-101 in or before april 2023 and the trial is expected to commence in 2023 pending regulatory clearance.
SNSE Ratings Summary
SNSE Quant Ranking